6 European Projects Found
Searched on 125080 European Projects
FINISHED
Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH)
Start date: Jun 1, 2015, End date: Nov 30, 2020,
The problem: finding the right patient for the right treatmentDespite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of appropriate outcome measures that can robustly identify patient benefit from a specific therapy. The lack of specific and sensi ...
Read Project
25
Partners Participants
FINISHED
Parasite-specific cyclic nucleotide phosphodiesterase inhibitors to target Neglected Parasitic Diseases (PDE4NPD)
Start date: Mar 1, 2014, End date: Feb 28, 2018,
This project aims to unite global efforts to target the highly druggable class of enzymes called cyclic nucleotide phosphodiesterases (PDEs) in the fight for neglected parasitic diseases (NPD). It will establish a drug discovery platform, PDE4NPD, that combines phenotypic screening with efficient target-centric drug discovery, including target validation, various strategies for compound screening, ...
Read Project
11
Partners Participants
FINISHED
European Lead Factory (EUC²LID)
Start date: Jan 1, 2013, End date: Dec 31, 2017,
The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provi ...
Read Project
34
Partners Participants
FINISHED
Kinetics for Drug Discovery (K4DD) (K4DD)
Start date: Nov 1, 2012, End date: Oct 31, 2017,
There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for clinical success. This ignorance may be one of the reasons for the high attrition rates in drug discovery, as it has been analyzed that many recently marketed drugs had indeed improved kinetic profiles. This hindsight knowledge needs to be converted into data-d ...
Read Project
21
Partners Participants
FINISHED
European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)
Start date: Jan 1, 2010, End date: Nov 30, 2016,
Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Read Project
34
Partners Participants
FINISHED
Pharmaceutical Medicine Training Programme (PHARMATRAIN)
Start date: May 1, 2009, End date: Apr 30, 2014,
"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Read Project
